Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 2,936.2	$ 3,452.8	$ 8,758.5	$ 11,120.0
Ronapreve | Roche Collaboration Agreement | Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 6.4	127.1	$ 230.9	361.8
Reimbursement of R&D expenses | Roche Collaboration Agreement | (R&D expense)/reduction of R&D expense
Disaggregation of Revenue [Line Items]
Revenues		$ 10.5		$ 138.3